Endoscopy 2012; 44(07): 707-710
DOI: 10.1055/s-0032-1309903
Case report/series
© Georg Thieme Verlag KG Stuttgart · New York

Endoscopic ablation of Barrett’s neoplasia with a new focal radiofrequency device: initial experience with the Halo60

B. Allen
1   Centre for Liver Disease and Digestive Disorders, The Royal Infirmary of Edinburgh, Edinburgh, UK
,
N. Kapoor
2   Gastrointestinal Unit, Royal Liverpool University Hospital, Liverpool, UK
,
R. Willert
3   Department of Gastroenterology, Central Manchester University Hospitals NHS Trust, Manchester, UK
,
H. McEwan
4   Upper Gastrointestinal Surgical Unit, Glasgow Royal Infirmary, Glasgow, UK
,
G. Fullarton
4   Upper Gastrointestinal Surgical Unit, Glasgow Royal Infirmary, Glasgow, UK
,
I. Penman
1   Centre for Liver Disease and Digestive Disorders, The Royal Infirmary of Edinburgh, Edinburgh, UK
› Institutsangaben
Weitere Informationen

Publikationsverlauf

submitted 05. März 2012

accepted after revision 27. April 2012

Publikationsdatum:
21. Juni 2012 (online)

Preview

Radiofrequency ablation (RFA) is an accepted treatment for the eradication of dysplastic Barrett’s esophagus (DBE) and residual Barrett’s esophagus after endoscopic resection of intramucosal adenocarcinoma. Circumferential balloon-based and focal catheter-based RFA devices are currently used (the Halo360 and Halo90). However, a new smaller focal ablation device (the Halo60) has been developed, which may be of benefit in patients with short tongues of Barrett’s neoplasia, small residual islands, difficult anatomy, or strictures. We report the first use of this device in 17 patients with either DBE or residual Barrett’s esophagus after endoscopic resection of intramucosal adenocarcinoma.